Campbell & Co Investment Adviser’s Meridian Bioscience Inc VIVO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-19,978	Closed	-$608K	–	998
2022 Q2	$608K	Buy	19,978 +7,165	+56%	+$194K	0.16%	207
2022 Q1	$333K	Buy	12,813 +1,713	+15%	+$40.7K	0.09%	445
2021 Q4	$226K	Buy	11,100 +240	+2%	+$4.6K	0.08%	486
2021 Q3	$209K	Buy	+10,860	New	+$216K	0.07%	505
2020 Q4	–	Sell	-12,243	Closed	-$208K	–	605
2020 Q3	$208K	Buy	+12,243	New	+$238K	0.15%	302
2020 Q1	–	Sell	-20,535	Closed	-$201K	–	582
2019 Q4	$201K	Buy	+20,535	New	+$193K	0.06%	590
2018 Q4	–	Sell	-11,266	Closed	-$168K	–	553
2018 Q3	$168K	Buy	+11,266	New	+$175K	0.11%	357
2018 Q2	–	Sell	-15,620	Closed	-$222K	–	563
2018 Q1	$222K	Buy	+15,620	New	+$231K	0.19%	271

Other funds holding VIVO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Campbell & Co Investment Adviser's VIVO Position: Q3 2022 in Review

Campbell & Co Investment Adviser sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 19,978 shares — an estimated $608K sold.

Campbell & Co Investment Adviser first reported a position in VIVO in Q1 2018 and held it in 8 quarters. The position peaked at $608K in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

Campbell & Co Investment Adviser reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
Campbell & Co Investment Adviser sold 19,978 Meridian Bioscience Inc shares in Q3 2022, an estimated $608K.
Campbell & Co Investment Adviser first reported a position in Meridian Bioscience Inc in Q1 2018 and held it in 8 quarters.
Campbell & Co Investment Adviser's Meridian Bioscience Inc position peaked at $608K in Q2 2022.
203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2022, filed 14 Nov 2022.